144 related articles for article (PubMed ID: 38040517)
21. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
Dasari V; Sinha D; Neller MA; Smith C; Khanna R
Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
[TBL] [Abstract][Full Text] [Related]
22. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens.
Engelmann I; Petzold DR; Kosinska A; Hepkema BG; Schulz TF; Heim A
J Med Virol; 2008 Mar; 80(3):467-77. PubMed ID: 18205230
[TBL] [Abstract][Full Text] [Related]
23. Immunoinformatics Approach to Design Novel Subunit Vaccine against the Epstein-Barr Virus.
Moin AT; Patil RB; Tabassum T; Araf Y; Ullah MA; Snigdha HJ; Alam T; Alvey SA; Rudra B; Mina SA; Akter Y; Zhai J; Zheng C
Microbiol Spectr; 2022 Oct; 10(5):e0115122. PubMed ID: 36094198
[TBL] [Abstract][Full Text] [Related]
24. A single tube PCR assay for simultaneous amplification of HSV-1/-2, VZV, CMV, HHV-6A/-6B, and EBV DNAs in cerebrospinal fluid from patients with virus-related neurological diseases.
Yamamoto T; Nakamura Y
J Neurovirol; 2000 Oct; 6(5):410-7. PubMed ID: 11031694
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
Aalto SM; Linnavuori K; Peltola H; Vuori E; Weissbrich B; Schubert J; Hedman L; Hedman K
J Med Virol; 1998 Nov; 56(3):186-91. PubMed ID: 9783683
[TBL] [Abstract][Full Text] [Related]
26. The expanding spectrum of herpesvirus infections of the nervous system.
Kleinschmidt-DeMasters BK; Gilden DH
Brain Pathol; 2001 Oct; 11(4):440-51. PubMed ID: 11556690
[TBL] [Abstract][Full Text] [Related]
27. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
28. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.
Dasari V; Bhatt KH; Smith C; Khanna R
Expert Rev Vaccines; 2017 Apr; 16(4):377-390. PubMed ID: 28276306
[TBL] [Abstract][Full Text] [Related]
29. The potential of currently unavailable herpes virus vaccines.
Rajčáni J; Bánáti F; Szenthe K; Szathmary S
Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728
[TBL] [Abstract][Full Text] [Related]
30. mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice.
Zhao GX; Bu GL; Liu GF; Kong XW; Sun C; Li ZQ; Dai DL; Sun HX; Kang YF; Feng GK; Zhong Q; Zeng MS
Adv Sci (Weinh); 2023 Dec; 10(35):e2302116. PubMed ID: 37890462
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis.
Scherlinger M; Alain S; Richez C
Joint Bone Spine; 2018 Mar; 85(2):259-260. PubMed ID: 28363825
[No Abstract] [Full Text] [Related]
32. Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2.
Plüß M; Mese K; Kowallick JT; Schuster A; Tampe D; Tampe B
Front Immunol; 2021; 12():784145. PubMed ID: 35116025
[TBL] [Abstract][Full Text] [Related]
33. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
34. Subclinical Cytomegalovirus and Epstein-Barr Virus Shedding Is Associated with Increasing HIV DNA Molecular Diversity in Peripheral Blood during Suppressive Antiretroviral Therapy.
Chaillon A; Nakazawa M; Rawlings SA; Curtin G; Caballero G; Scott B; Anderson C; Gianella S
J Virol; 2020 Sep; 94(19):. PubMed ID: 32641485
[TBL] [Abstract][Full Text] [Related]
35. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA- and DNA-in situ hybridization.
Mehraein Y; Lennerz C; Ehlhardt S; Remberger K; Ojak A; Zang KD
Mod Pathol; 2004 Jul; 17(7):781-9. PubMed ID: 15044921
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus and Epstein-Barr virus subtypes--the search for clinical significance.
Puchhammer-Stöckl E; Görzer I
J Clin Virol; 2006 Aug; 36(4):239-48. PubMed ID: 16697698
[TBL] [Abstract][Full Text] [Related]
37. mRNA vaccines against respiratory viruses.
Whitaker JA; Sahly HME; Healy CM
Curr Opin Infect Dis; 2023 Oct; 36(5):385-393. PubMed ID: 37462930
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
39. mRNA-Based Vaccine Designing against Epstein-Barr Virus to Induce an Immune Response Using Immunoinformatic and Molecular Modelling Approaches.
Althurwi HN; Alharthy KM; Albaqami FF; Altharawi A; Javed MR; Muhseen ZT; Tahir Ul Qamar M
Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36293632
[TBL] [Abstract][Full Text] [Related]
40. Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection.
Sakamoto Y; Mariya Y; Kubo K
Tohoku J Exp Med; 2012 Aug; 227(4):307-11. PubMed ID: 22850617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
